Today's Perilous Reversal Stock: Sarepta Therapeutics (SRPT)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Sarepta Therapeutics ( SRPT) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Sarepta Therapeutics as such a stock due to the following factors:

  • SRPT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $15.3 million.
  • SRPT has traded 58,096 shares today.
  • SRPT is down 6% today.
  • SRPT was up 11.4% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SRPT with the Ticky from Trade-Ideas. See the FREE profile for SRPT NOW at Trade-Ideas

More details on SRPT:

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Currently there are 6 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 10 rate it a hold.

The average volume for Sarepta Therapeutics has been 797,400 shares per day over the past 30 days. Sarepta has a market cap of $548.8 million and is part of the health care sector and drugs industry. The stock has a beta of 1.20 and a short float of 32.8% with 12.05 days to cover. Shares are down 8.3% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Sarepta Therapeutics Chart Patterns Look Good

Verastem Shares Are Exploding 50% -- Here's Why

Watch the Key Technical Levels

Net Seller, but Itching to Put More Cash to Work